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An 80-year-old man with previous intravesicular bacille Calmette-Guérin therapy developed mass
lesions of the lower thoracic spine. Metastatic disease was suspected. The patient underwent a course of
radiation; however, biopsy later demonstrated ﬁbrosis and cultures grew Mycobacterium bovis. The
patient was treated with a course of isoniazid, rifampin, and ethambutol.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Intravesicular bacille Calmette-Guérin (BCG) has become an
accepted approach for treating uroepithelial cancers. It is believed
to exhibit antitumor effect via activation of an inﬂammatory
cascade. This inﬂammatory response can also cause a systemic in-
ﬂammatory reaction or lead to localized or systemicMycobacterium
bovis infection. Sites of infection range from localized cystitis to
disseminated bacteremia, with possible secondary seeding of lung
or bone. Though uncommon, M bovis infection should be consid-
ered in patients with history of intravesicular BCG therapy when
presenting with new lumbar spine pain or destructive bone lesions.Case presentation
An 80-year-old man with history of bladder cancer underwent
treatment with intravesicular BCG between 2008 and 2010. More
than 1 year after treatment, he developed progressive neck pain
with right arm numbness and tingling. He underwent cervical
discectomy and decompression. He subsequently developed difﬁ-
culty ambulating, fatigue, lethargy, and 40-pound weight loss overBY-NC-ND license (http://
: þ1-913-945-6916.
).
Published by Elsevier Inc. All righthe ensuing 5 months. Magnetic resonance imaging and computed
tomography scans of the thoracic spine demonstrated a lytic mass
at T9-T10. Bone biopsy revealed ﬁbrosis. Positron emission to-
mography scan showed increased uptake. With concern for ma-
lignancy, he was treated with 10 cycles of radiation therapy. The
pain did not improve and he had worsening neurologic function.
Repeat magnetic resonance imaging showed retropulsion of the
remaining vertebral body causing impingement. He was referred
for surgical stabilization. At that time, he denied fevers, chills, night
sweats, or further constitutional symptoms. He reported no history
of BCG vaccination, recent travel, tuberculosis, or animal exposures.
On examination, he was afebrile with no notable ﬁndings aside
from bilateral lower extremity weakness and sensory disturbance.
Laboratory revealed a white blood cell count of 6700 (92% neu-
trophils, 2% lymphocytes, and 6% monocytes), normocytic anemia
with hemoglobin 11.9 g, and a platelet count of 85,000. Creatinine
and hepatic transaminases were normal, with albumin low at
1.9 g/dL. A T-spot.TB test (Oxford Diagnostic Laboratories, Memphis,
TN) was negative.
He underwent T6-L1 minimally invasive thoracolumbar fusion
with T9-T10 laminectomy. No purulence was visualized; however, a
portion of the posterior lamina was found to have been eroded by
soft tissue and the ligament appeared dark in color. A biopsy of the
T10 vertebral body was performed and specimens were sent for
culture and histopathology (Fig. 1).
Hewas started on empiric therapywith intravenous vancomycin
and ertapenem. Frozen and permanent sections of the associatedts reserved.
Figure 1. T10 bone and ﬁbrocollagenous tissue; no evidence of malignancy. Image
courtesy of Dr. Maura O’Neil, M.D.
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Isoniazid 300 mg orally daily, rifampin 600 mg orally daily,
ethambutol 1200 mg orally daily, and pyridoxine 50 mg orally daily
were started. Further surgical treatment was not undertaken given
the patient’s advanced age and deconditioned state. Vancomycin
and ertapenem were discontinued. The Mycobacterium was later
identiﬁed as M bovis. The isolate was susceptible to isoniazid,
rifampin, and streptomycin and resistant to pyrazinamide. He was
discharged to a long-term care facility and completed 2 months of
ethambutol and 6 months of isoniazid and rifampin along with
physical therapy.Discussion
M bovis is a member of the tuberculosis complex that includesM
tuberculosis, M africanum, and M microti. It is the primary cause of
tuberculosis complex infections in cattle and other mammals but is
also associated with disease in humans (approximately 1%-2% of
tuberculosis complex infections). In humans most cases involve
consumption of infected cow’s milk products or administration
of BCG.
BCG is a vaccine prepared from a live attenuated strain of M
bovis. It has been used since the early 20th century to prevent
tuberculosis and other mycobacterial infections. BCG was ﬁrstTable 1
Published cases of spinal Mycobacterium bovis infection
Case Author Age Time to Disease From BCG
1 Abu-Nader, R6 76 7 y
2 Aljada, IS7 79 2.5 y
4 Katz, DS8 67 1.3 y
5 Morgan MB9 77 8 mo
6 Nikaido, T10 86 1.8 y
7 Samadian, S11 94 5 mo
8 Colebatch, AN12 67 5 y
9 Civen, R13 81 7 mo
10 Fishman, JR14 90 1.3 y
11 Patel, AR15 66 5 mo
12 Mavrogenis, AF16 79 12 y
13 Rozenblit, A17 76 5.8 y
14 Dahl, T18 69 1 y
15 Presented case 80 3 y
BCG, bacille Calmette-Guérin; cipro, ciproﬂoxacin; ETM, Ethambutol; INH, Isoniazid; PYRused as an immunomodulatory agent for superﬁcial urothelial
carcinomas in 1976.When BCG is instilled into the bladder, it binds
to ﬁbronectin expressed on the urothelium and is internalized by
local cells. This provokes an inﬂammatory response with mono-
nuclear cell inﬁltration and class-II major histocompatibility
complex molecule expression by the malignant cells. The malig-
nant cell then becomes a target for lymphokine-activated killer
cells and BCG antigen-presenting cells.1 However, intravesiciular
BCG administration can also lead to an exaggerated inﬂammatory
response and localized and disseminated infection. Localized
disease includes cystitis and prostatitis and generally presents
early after treatment. More widespread disease can present as a
sepsis syndrome, induced either by a cytokine storm leading to a
serum sickness or overt bacteremia. This reaction generally occurs
acutely but has been reported several months or rarely years after
treatment.2-4
More common delayed complications of intravesicular BCG
administration include granulomatous hepatitis and osteomye-
litis. Bone disease most commonly affects the spine, presumably
because of spread from the urinary tract through the Batson
venous plexus, although the incidence remains overall very rare.
A computer-assisted search of English literature using PubMed
identiﬁed case reports of BCG infection of the spine intravesicular
administration of BCG. Keywords used in the search were
“Osteomyelitis and spine and BCG,” “Spine and infection and
BCG,” “Spondylitis and BCG,” and “Discitis and BCG”. In addition
to the PubMed search, publications referenced in the footnotes of
other case reports were reviewed for additional cases. Fourteen
additional cases of spinal infection with M bovis in patients
treated with intravesicular BCG treatments were identiﬁed. Pa-
tient ages ranged from 66 to 94 years. Time from treatment to
disease identiﬁcation ranged from 5 months to 12 years. Most
patients were started on a 4-drug antituberculosis regimen that
was narrowed to isoniazid, and rifampin with or without
ethambutol once M bovis was identiﬁed, given its inherent
resistance to pyrazinamide. Half of the patients required surgical
intervention including debridement with or without spinal sta-
bilization. Polymerase chain reaction testing proved helpful in
making a diagnosis in several cases, and the rest were diagnosed
via culture of M bovis from the infected area (Table 1).Conclusion
Despite the relatively low incidence of spinal infection after BCG
therapy, osteomyelitis and discitis secondary to M bovis should be
considered in patients with an indolent course of back pain with aArea of Disease Treatment Surgical Intervention?
T6-7 INH þ RIF þ ETM No
L3 INH þ RIF No
L4-5 INH þ RIF þ PYR Yes
T11-L1 INH þ RIF þ ETM Yes
T12-L1 INH þ RIF þ ETM No
L1-2 INH þ RIF þ ETM No
L4-5 INH þ RIF No
T12-L1 INH þ RIF Yes
T11-12 INH þ RIF þ ETM þ PYR Yes
T10-11 INH þ RIF þ ETM No
L3-4 INH þ RIF þ ETM Yes
L4-5 INH þ RIF þ ETM þ cipro Yes
L3-4 INH þ RIF Yes
T9-10 INH þ RIF þ ETM Yes
, Pyrazinamide; RIF, Rifampin.
J.R. Newman et al. / Urology Case Reports 2 (2014) 142e144144history of intravesicular BCG therapy. The incidence of M bovis in-
fections in general may be under-reported in those patients with
additional exposures including infected animals, contaminated
cheese products, and prior BCG vaccination.5 Antituberculous
therapy, in addition to standard empiric antimicrobial therapy,
should be considered as workup for the pathogen ensues.
Conﬂict of interest
The authors have no ﬁnancial disclosures and no actual or po-
tential conﬂict of interests to disclose.
References
1. Askeland EJ, Newton MR, O’Donnell MA, Luo Y. Bladder Cancer immuno-
therapy: BCG and beyond. Adv Urol. 2012;2012:181987.
2. Izes JK, Bihrle 3rd W, Thomas CB. Corticosteroid-associated fatal mycobacterial
sepsis occurring 3 years after instillation of intravesical bacillus Calmette-
Guerin. J Urol. 1993;150:1498e1500.
3. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin
North Am. 1992;19:565e572.
4. Rival G, Garot D, Mercier E, et al. Acute respiratory failure and septic shock
induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy.
Presse Med. 2006;35:980e982.
5. Samadian S, Phillips FM, Deeab D. Mycobacterium bovis vertebral osteomyelitis
and discitis with adjacent mycotic abdominal aortic aneurysm caused by
intravesical BCG therapy: a case report in an elderly gentleman. Age Ageing.
2013;42:129e131.
6. Abu-Nader R, Terrell CL. Mycobacterium bovis vertebral osteomyelitis as a
complication of intravesical BCG use. Mayo Clin Proc. 2002;77:393e397.7. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing verte-
bral osteomyelitis (Pott’s disease) following intravesical BCG therapy. J Clinical
Microbiol. 1999;37:2106e2108.
8. Katz DS, Wogalter H, D’Esposito RF, Cunha BA. Mycobacterium bovis vertebral
osteomyelitis and psoas abscess after intravesical BCG therapy for bladder
carcinoma. Urology. 1992;40:63e66.
9. Morgan MB, Iseman MD. Mycobacterium bovis vertebral osteomyelitis as a
complication of intravesical administration of Bacille Calmette-Guerin. The Am J
Med. 1996;100:372e373.
10. Nikaido T, Ishibashi K, Otani K, et al. Mycobacterium bovis BCG vertebral
osteomyelitis after intravesical BCG therapy, diagnosed by PCR-based genomic
deletion analysis. J Clin Microbiol. 2007;45:4085e4087.
11. Samadian S, Phillips FM, Deeab D. Mycobacterium bovis vertebral osteomyelitis
and discitis with adjacent mycotic abdominal aortic aneurysm caused by
intravesical BCG therapy: a case report in an elderly gentleman. Age Ageing.
2013;42:129e131.
12. Colebatch AN, Mounce KE. Mycobacterium bovis discitis as a complication
of intravesical Bacillus Calmette-Guerin therapy. J Clin Rheumatol. 2010;16:74e75.
13. Civen R, Berlin G, Panosian C. Vertebral osteomyelitis after intravesical
administration of bacille Calmette-Guerin. Clin Infect Dis. 1994;18:1013e1014.
14. Fishman JR, Walton DT, Flynn NM, et al. Tuberculous spondylitis as a complica-
tion of intravesical bacillus Calmette-Guerin therapy. J Urol. 1993;149:584e587.
15. Patel AR, Sabanegh ES, Jones JS, et al. Bacillus Calmette-Guerin osteomyelitis
mimicking spinal metastasis from urothelial cell carcinoma of the bladder. Eur
Urol. 2010;58:934e937.
16. Mavrogenis AF, Sakellariou VI, Tsiodras S, Papagelopoulos PJ. Late Mycobacte-
rium bovis spondylitis after intravesical BCG therapy. Joint Bone Spine. 2009;76:
296e300.
17. Rozenblit A, Wasserman E, Marin ML, et al. Infected aortic aneurysm and
vertebral osteomyelitis after intravesical bacillus Calmette-Guerin therapy. AJR
Am J Roentgenol. 1996;167:711e713.
18. Dahl T, Lange C, Odegard A, et al. Ruptured abdominal aortic aneurysm sec-
ondary to tuberculous spondylitis. Int Angiol. 2005;24:98e101.
